{
    "symbol": "ARWR",
    "quarter": 4,
    "year": 2022,
    "date": "2022-11-28 20:44:05",
    "content": " In the MUIR study in subjects with mixed dyslipidemia who had baseline average TGs of 220 mg/dL, non-HDL of 150, LDL cholesterol of 110, and ApoB of 95, remnant cholesterol of 46, and HDL cholesterol of 42mg/dL, treatment with ARO-APOC3 at doses of 10 mg, 25 mg, and 50 mg resulted in substantial reductions of APOC3 of 80%, TGs of 65%, non-HDL cholesterol of 25%, LDL-C of 20%, and ApoB of 20%, remnant cholesterol decreased by 60%, and an increase in HDL cholesterol increased by 50%."
}